Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021
07 juil. 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
Presentation to highlight Company’s current clinical study of lead compound LB-100 for Small Cell Lung Cancer ALTADENA, CA, July 07, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc....
Cancer Genetics, Inc. is Among the First To Drive New FDA-Approved Testing Paradigm for Non-Small Cell Lung Cancer Patients by Offering Thermo Fisher Scientific’s Oncomine Dx Target Test
02 nov. 2017 07h30 HE
|
Cancer Genetics, Inc.
Thermo Fisher’s multi-biomarker test helps match lung cancer patients to FDA-approved therapies in days instead of weeksCGI and Thermo Fisher are collaborating with pharmaceutical partners and...